Lead Product(s): Rho-associated kinase-Human corneal endothelial cells
Therapeutic Area: Ophthalmology Product Name: AE101
Highest Development Status: Preclinical Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Arctic Vision
Deal Size: $35.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement May 14, 2021
Arctic Vision will develop and market ActualEyes’ AE-101, for the treatment of corneal endothelial dysfunction in Greater China and South Korea. ARVN901 (AE-101) is a novel cell-injection therapy developed using cultured hCECs combined with a ROCK inhibitor.